Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity

Importance MicroRNAs (miRNAs) are promising multiple sclerosis (MS) biomarkers. Establishing the association between miRNAs and magnetic resonance imaging (MRI) measures of disease severity will help define their significance and potential impact. Objective To correlate circulating miRNAs in the serum of patients with MS to brain and spinal MRI. Design, Setting, and Participants A cross-sectional study comparing serum miRNA samples with MRI metrics was conducted at a tertiary MS referral center. Two independent cohorts (41 and 79 patients) were retrospectively identified from the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital. Expression of miRNA was determined by locked nucleic acid–based quantitative real-time polymerase chain reaction. Spearman correlation coefficients were used to test the association between miRNA and brain lesions (T2 hyperintense lesion volume [T2LV]), the ratio of T1 hypointense lesion volume [T1LV] to T2LV [T1:T2]), brain atrophy (whole brain and gray matter), and cervical spinal cord lesions (T2LV) and atrophy. The study was conducted from December 2013 to April 2016. Main Outcomes and Measures miRNA expression. Results Of the 120 patients included in the study, cohort 1 included 41 participants (7 [17.1%] men), with mean (SD) age of 47.7 (9.5) years; cohort 2 had 79 participants (26 [32.9%] men) with a mean (SD) age of 43.0 (7.5) years. Associations between miRNAs and MRIs were both protective and pathogenic. Regarding miRNA signatures, a topographic specificity differed for the brain vs the spinal cord, and the signature differed between T2LV and atrophy/destructive measures. Four miRNAs showed similar significant protective correlations with T1:T2 in both cohorts, with the highest for hsa.miR.143.3p (cohort 1: Spearman correlation coefficient rs = −0.452, P = .003; cohort 2: rs = −0.225, P = .046); the others included hsa.miR.142.5p (cohort 1: rs = −0.424, P = .006; cohort 2: rs = −0.226, P = .045), hsa.miR.181c.3p (cohort 1: rs = −0.383, P = .01; cohort 2: rs = −0.222, P = .049), and hsa.miR.181c.5p (cohort 1: rs = −0.433, P = .005; cohort 2: rs = −0.231, P = .04). In the 2 cohorts, hsa.miR.486.5p (cohort 1: rs = 0.348, P = .03; cohort 2: rs = 0.254, P = .02) and hsa.miR.92a.3p (cohort 1: rs = 0.392, P = .01; cohort 2: rs = 0.222, P = .049) showed similar significant pathogenic correlations with T1:T2; hsa.miR.375 (cohort 1: rs = −0.345, P = .03; cohort 2: rs = −0.257, P = .022) and hsa.miR.629.5p (cohort 1: rs = −0.350, P = .03; cohort 2: rs = −0.269, P = .02) showed significant pathogenic correlations with brain atrophy. Although we found several miRNAs associated with MRI outcomes, none of these associations remained significant when correcting for multiple comparisons, suggesting that further validation of our findings is needed. Conclusions and Relevance Serum miRNAs may serve as MS biomarkers for monitoring disease progression and act as surrogate markers to identify underlying disease processes.

[1]  R. Gold,et al.  Regulated microRNAs in the CSF of patients with multiple sclerosis , 2012, Neurology.

[2]  Daniel B. Martin,et al.  Circulating microRNAs as stable blood-based markers for cancer detection , 2008, Proceedings of the National Academy of Sciences.

[3]  Simon Hametner,et al.  Multiple sclerosis deep grey matter: the relation between demyelination, neurodegeneration, inflammation and iron , 2014, Journal of Neurology, Neurosurgery & Psychiatry.

[4]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[5]  Rohit Bakshi,et al.  Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis , 2015, Journal of Neurology.

[6]  Rohit Bakshi,et al.  MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis , 2014, Journal of the Neurological Sciences.

[7]  F. Barkhof,et al.  HLA-DRB1*1501 and spinal cord magnetic resonance imaging lesions in multiple sclerosis. , 2009, Archives of neurology.

[8]  C. Zimmer,et al.  Tissue damage within normal appearing white matter in early multiple sclerosis: assessment by the ratio of T1- and T2-weighted MR image intensity , 2016, Journal of Neurology.

[9]  D. Arnold,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[10]  Konstantinos J. Mavrakis,et al.  A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL) , 2011, Nature Genetics.

[11]  Sheena L. Dupuy,et al.  An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in multiple sclerosis , 2016, Journal of Neurology.

[12]  R. Bakshi,et al.  Measurement of Brain and Spinal Cord Atrophy by Magnetic Resonance Imaging as a Tool to Monitor Multiple Sclerosis , 2005, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[13]  M. Nagarkatti,et al.  MicroRNAs associated with the pathogenesis of multiple sclerosis , 2016, Journal of Neuroimmunology.

[14]  R. Gandhi.  miRNA in multiple sclerosis: search for novel biomarkers , 2015, Multiple sclerosis.

[15]  R. Bakshi,et al.  Use of Magnetic Resonance Imaging to Visualize Leptomeningeal Inflammation in Patients With Multiple Sclerosis: A Review , 2017, JAMA neurology.

[16]  Olivier Gout,et al.  Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis , 2014, Annals of neurology.

[17]  Zhiqiang Ma,et al.  Nrf2 Weaves an Elaborate Network of Neuroprotection Against Stroke , 2017, Molecular Neurobiology.

[18]  H. Lassmann,et al.  Pathology of multiple sclerosis and related inflammatory demyelinating diseases. , 2014, Handbook of clinical neurology.

[19]  Guihua Sun,et al.  MicroRNA-486 regulates normal erythropoiesis and enhances growth and modulates drug response in CML progenitors. , 2015, Blood.

[20]  K. Abe,et al.  Time-Dependent Profiles of MicroRNA Expression Induced by Ischemic Preconditioning in the Gerbil Hippocampus , 2015, Cell transplantation.

[21]  F. Barkhof,et al.  Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis , 1998, Neurology.

[22]  M. Maletic-Savatic,et al.  MicroRNA Profiling Reveals Unique miRNA Signatures in IGF-1 Treated Embryonic Striatal Stem Cell Fate Decisions in Striatal Neurogenesis In Vitro , 2014, BioMed research international.

[23]  J. Kurtzke.  On the origin of EDSS. , 2015, Multiple sclerosis and related disorders.

[24]  L. Turka,et al.  Regulation of T Cell Homeostasis and Responses by Pten , 2012, Front. Immun..

[25]  M. A. Horsfield,et al.  Rapid semi-automatic segmentation of the spinal cord from magnetic resonance images: Application in multiple sclerosis , 2010, NeuroImage.

[26]  Rohit Bakshi,et al.  A semiautomated measure of whole-brain atrophy in multiple sclerosis , 2003, Journal of the Neurological Sciences.

[27]  H. Cao,et al.  MicroRNA-92a promotes metastasis of nasopharyngeal carcinoma by targeting the PTEN/AKT pathway , 2016, OncoTargets and therapy.

[28]  S. Miller,et al.  Molecular mechanisms of T‐cell receptor and costimulatory molecule ligation/blockade in autoimmune disease therapy , 2009, Immunological reviews.

[29]  C. Guttmann,et al.  An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2 , 2014, Neuroreport.

[30]  M. Filippi.  MRI measures of neurodegeneration in multiple sclerosis: implications for disability, disease monitoring, and treatment , 2014, Journal of Neurology.

[31]  Baojun Zhang,et al.  miR-17-92 Cluster Targets Phosphatase and Tensin Homology and Ikaros Family Zinc Finger 4 to Promote TH17-mediated Inflammation* , 2014, The Journal of Biological Chemistry.

[32]  Rohit Bakshi,et al.  The relationship between whole brain volume and disability in multiple sclerosis: A comparison of normalized gray vs. white matter with misclassification correction , 2005, NeuroImage.

[33]  D. Chaplin,et al.  Inhibition of the catalytic function of activation-induced cytidine deaminase promotes apoptosis of germinal center B cells in BXD2 mice. , 2011, Arthritis and rheumatism.

[34]  Grace X. Y. Zheng,et al.  Dynamic regulation of miRNA expression in ordered stages of cellular development. , 2007, Genes & development.

[35]  H. Weiner,et al.  Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis , 2013, Annals of neurology.

[36]  F. Barkhof,et al.  Spinal cord abnormalities in recently diagnosed MS patients , 2004, Neurology.

[37]  S. Baranzini,et al.  Blood miRNA expression pattern is a possible risk marker for natalizumab-associated progressive multifocal leukoencephalopathy in multiple sclerosis patients , 2014, Multiple sclerosis.

[38]  Rohit Bakshi,et al.  Whole Brain Volume Measured from 1.5T versus 3T MRI in Healthy Subjects and Patients with Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[39]  J S Wolinsky,et al.  EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis , 2006, European journal of neurology.

[40]  Rohit Bakshi,et al.  Gray and white matter brain atrophy and neuropsychological impairment in multiple sclerosis , 2006, Neurology.

[41]  Margaret S. Ebert,et al.  Roles for MicroRNAs in Conferring Robustness to Biological Processes , 2012, Cell.

[42]  R. Bakshi,et al.  Approaches to Normalization of Spinal Cord Volume: Application to Multiple Sclerosis , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[43]  Xi Chen,et al.  Serum MicroRNA Profiles Serve as Novel Biomarkers for the Diagnosis of Alzheimer's Disease , 2015, Disease markers.

[44]  Further to the origin of EDSS (Response to: L. Kappos et al: "On the origin of Neurostatus" Multiple Sclerosis and Related Disorders 2015; 4: 186). , 2015, Multiple sclerosis and related disorders.

[45]  Rohit Bakshi,et al.  Role of MRI in multiple sclerosis I: inflammation and lesions. , 2004, Frontiers in bioscience : a journal and virtual library.

[46]  Juhyun Song,et al.  Apoptosis signal-regulating kinase 1 (ASK1) is linked to neural stem cell differentiation after ischemic brain injury , 2013, Experimental & Molecular Medicine.

[47]  Sofie Sølvsten Sørensen,et al.  miRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer’s disease and other types of dementia – an exploratory study , 2016, Translational Neurodegeneration.

[48]  K. Shroyer,et al.  miR-181a-5p Inhibits Cancer Cell Migration and Angiogenesis via Downregulation of Matrix Metalloproteinase-14. , 2015, Cancer research.

[49]  R. Bakshi,et al.  Quality of life and its relationship to brain lesions and atrophy on magnetic resonance images in 60 patients with multiple sclerosis. , 2000, Archives of neurology.

[50]  Massimiliano Calabrese,et al.  Measurement and clinical effect of grey matter pathology in multiple sclerosis , 2012, The Lancet Neurology.

[51]  Susan A Gauthier,et al.  A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. , 2006, Autoimmunity reviews.

[52]  A. Ward,et al.  The Ikaros gene family: transcriptional regulators of hematopoiesis and immunity. , 2011, Molecular immunology.

[53]  M. Horsfield,et al.  T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis , 2015, BMC Neurology.

[54]  P. Zigrino,et al.  Monocyte/macrophage MMP-14 modulates cell infiltration and T-cell attraction in contact dermatitis but not in murine wound healing. , 2013, The American journal of pathology.

[55]  C. Guttmann,et al.  Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study , 2012, Journal of the Neurological Sciences.

[56]  Christine S. Siegismund,et al.  MicroRNA Profiling of CSF Reveals Potential Biomarkers to Detect Alzheimer`s Disease , 2015, PloS one.

[57]  M. Nagarkatti,et al.  Expression, Regulation and Function of MicroRNAs in Multiple Sclerosis , 2014, International journal of medical sciences.

[58]  Pilar Martín,et al.  Is CD69 an effective brake to control inflammatory diseases? , 2013, Trends in molecular medicine.

[59]  G. Cutter,et al.  MRI as a marker for disease heterogeneity in multiple sclerosis , 2005, Neurology.

[60]  K. Lam,et al.  Mir-17–92 regulates bone marrow homing of plasma cells and production of immunoglobulin G2c , 2015, Nature Communications.

[61]  F. Barkhof,et al.  Multiple sclerosis , 2003, Neurology.

[62]  Sheena L. Dupuy,et al.  The Effect of Fingolimod on Conversion of Acute Gadolinium‐Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis , 2015, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[63]  Katie Podshivalova,et al.  MicroRNA regulation of T-lymphocyte immunity: modulation of molecular networks responsible for T-cell activation, differentiation, and development. , 2013, Critical reviews in immunology.

[64]  Rohit Bakshi,et al.  MRI in multiple sclerosis: current status and future prospects , 2008, The Lancet Neurology.

[65]  F. Turkheimer,et al.  Microglia activation in multiple sclerosis black holes predicts outcome in progressive patients: An in vivo [(11)C](R)-PK11195-PET pilot study , 2014, Neurobiology of Disease.

[66]  J. Mendell,et al.  MicroRNAs in Stress Signaling and Human Disease , 2012, Cell.

[67]  Massimo Filippi,et al.  Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: a multicentre, double-blind, randomised, placebo-controlled study , 2006, The Lancet Neurology.

[68]  E. Akirav,et al.  Remyelination in multiple sclerosis: Cellular mechanisms and novel therapeutic approaches , 2015, Journal of neuroscience research.

[69]  Rohit Bakshi,et al.  Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. , 2008, Archives of neurology.

[70]  Jerry L Prince,et al.  Spinal Cord Normalization in Multiple Sclerosis , 2014, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[71]  X. Chen,et al.  Secreted microRNAs: a new form of intercellular communication. , 2012, Trends in cell biology.

[72]  J. Abdullah,et al.  IGF-1 Acts as Controlling Switch for Long-term Proliferation and Maintenance of EGF/FGF-responsive Striatal Neural Stem Cells , 2013, International journal of medical sciences.

[73]  F. Barkhof,et al.  Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis , 1996, Neurology.

[74]  M. Soleimani,et al.  Involvement of MicroRNA in T-Cell Differentiation and Malignancy , 2015, International journal of hematology-oncology and stem cell research.

[75]  L. Kappos,et al.  Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects. , 2012, Clinical immunology.

[76]  Rohit Bakshi,et al.  Gray matter involvement in multiple sclerosis , 2007, Neurology.

[77]  H. Lassmann,et al.  Prospects of Transcript Profiling for mRNAs and MicroRNAs Using Formalin‐Fixed and Paraffin‐Embedded Dissected Autoptic Multiple Sclerosis Lesions , 2012, Brain pathology.

[78]  S. Booth,et al.  MicroRNA abundance is altered in synaptoneurosomes during prion disease , 2016, Molecular and Cellular Neuroscience.

[79]  J. Goverman,et al.  Differential regulation of central nervous system autoimmunity by TH1 and TH17 cells , 2008, Nature Medicine.

[80]  M. Hecker,et al.  MicroRNAs in multiple sclerosis and experimental autoimmune encephalomyelitis. , 2012, Autoimmunity reviews.

[81]  Rohit Bakshi,et al.  The Relationships among MRI‐Defined Spinal Cord Involvement, Brain Involvement, and Disability in Multiple Sclerosis , 2012, Journal of neuroimaging : official journal of the American Society of Neuroimaging.

[82]  S. Lawler,et al.  Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity. , 2011, Brain : a journal of neurology.

[83]  P. Wei,et al.  MiR-92a Promotes Cell Metastasis of Colorectal Cancer Through PTEN-Mediated PI3K/AKT Pathway , 2015, Annals of Surgical Oncology.

[84]  R. Bakshi,et al.  Whole-brain atrophy in multiple sclerosis measured by automated versus semiautomated MR imaging segmentation. , 2004, AJNR. American journal of neuroradiology.

[85]  U. A. Ørom,et al.  MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. , 2008, Molecular cell.

[86]  D. Louis,et al.  PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. , 2001, Genes & development.

[87]  H. Weiner,et al.  Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[88]  J. Steitz,et al.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.

[89]  Fei Li,et al.  Abundant conserved microRNA target sites in the 5′-untranslated region and coding sequence , 2009, Genetica.

[90]  Jamie L. Marshall,et al.  MicroRNA-486-dependent modulation of DOCK3/PTEN/AKT signaling pathways improves muscular dystrophy-associated symptoms. , 2014, The Journal of clinical investigation.